
Royalty Pharma plc: updates and filings
Price
$68.39
November 19, 2026Market cap $29.4B
What Ploutos Investor adds for Royalty Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
December 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026FilingForm13F-NT
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Aug 17, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 14, 2026FilingForm13F-NT
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jun 16, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 4, 2026Shareholder voteForm8-K
- May 28, 2026Material agreement entered, new material financial obligationForm8-K
- May 14, 2026FilingForm13F-NT
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 13, 2026Regulation FD disclosureForm8-K
- Apr 10, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 10, 2026Additional annual meeting materialFormDEFA14A
- Apr 10, 2026Annual meeting proxy statementFormDEF 14A
- Apr 1, 2026FilingForm13F-NT
- Feb 20, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 11, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 11, 2026Results of operationsForm8-K
- Dec 22, 2025Officer or director changeForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 13F-NT | Filing | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Aug 17, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 14, 2026 | 13F-NT | Filing | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jun 16, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 4, 2026 | 8-K | Shareholder vote | Document |
| May 28, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| May 14, 2026 | 13F-NT | Filing | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 13, 2026 | 8-K | Regulation FD disclosure | Document |
| Apr 10, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 10, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 10, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 1, 2026 | 13F-NT | Filing | Document |
| Feb 20, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 11, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 11, 2026 | 8-K | Results of operations | Document |
| Dec 22, 2025 | 8-K | Officer or director change | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 13, 2020.
The full analysis
What do Royalty Pharma's filings show?
The filings are where every one of Royalty Pharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.